Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Market Overview:

The global multiple sclerosis therapies market exhibited moderate growth during 2015-2020. Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further. Looking forward, IMARC Group expects the global multiple sclerosis therapies market to grow at a CAGR of around 5% during the forecast period (2021-2026).

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug, drug type, route of administration and distribution channel.

Breakup by Drug:

  • Immunomodulators
    • Copaxone
    • Avonex/Plegridy
    • Gilneya
    • Tysabri
    • Betaseron/Extavia
    • Tecifidera
    • Rebif
    • Ampyra
  • Immunosuppressants
    • Aubagio
    • Lemtrada
    • Ocrelizumab
    • Zinbryta
       

Breakup by Drug Type:

  • Biologic Drugs
  • Small Molecule Drugs
     

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Intravenous
     

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Report Coverages:

Report Features Details
Base Year of the Analysis 2020
Historical Period 2015-2020
Forecast Period 2021-2026
Units US$ Billion
Segment Coverage Drug, Drug Type, Route of Administration, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple sclerosis therapies market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology 

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Multiple Sclerosis Therapies Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Drug
    6.1    Immunomodulators
        6.1.1 Market Trends
        6.1.2 Major Types
              6.1.2.1 Copaxone
              6.1.2.2 Avonex/Plegridy
              6.1.2.3 Gilneya
              6.1.2.4 Tysabri
              6.1.2.5 Betaseron/Extavia
              6.1.2.6 Tecifidera
              6.1.2.7 Rebif
              6.1.2.8 Ampyra
        6.1.3 Market Forecast
    6.2    Immunosuppressants
        6.2.1 Market Trends
        6.2.2 Major Types
              6.2.2.1 Aubagio
              6.2.2.2 Lemtrada
              6.2.2.3 Ocrelizumab
              6.2.2.4 Zinbryta
        6.2.3 Market Forecast
7    Market Breakup by Drug Type
    7.1    Biologic Drugs
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Small Molecule Drugs
        7.2.1 Market Trends
        7.2.2 Market Forecast
8    Market Breakup by Route of Administration
    8.1    Oral
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Injectable
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Intravenous
        8.3.1 Market Trends
        8.3.2 Market Forecast
9    Market Breakup by Distribution Channel
    9.1    Hospitals Pharmacies
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Retail Pharmacies
        9.2.1 Market Trends
        9.2.2 Market Forecast
    9.3    Online Pharmacies
        9.3.1 Market Trends
        9.3.2 Market Forecast
10    Market Breakup by Region
    10.1    North America
        10.1.1 United States
           10.1.1.1 Market Trends
           10.1.1.2 Market Forecast
        10.1.2 Canada
           10.1.2.1 Market Trends
           10.1.2.2 Market Forecast
    10.2    Asia Pacific
        10.2.1 China
           10.2.1.1 Market Trends
           10.2.1.2 Market Forecast
        10.2.2 Japan
           10.2.2.1 Market Trends
           10.2.2.2 Market Forecast
        10.2.3 India
           10.2.3.1 Market Trends
           10.2.3.2 Market Forecast
        10.2.4 South Korea
           10.2.4.1 Market Trends
           10.2.4.2 Market Forecast
        10.2.5 Australia
           10.2.5.1 Market Trends
           10.2.5.2 Market Forecast
        10.2.6 Indonesia
           10.2.6.1 Market Trends
           10.2.6.2 Market Forecast
        10.2.7 Others
           10.2.7.1 Market Trends
           10.2.7.2 Market Forecast
    10.3    Europe
        10.3.1 Germany
           10.3.1.1 Market Trends
           10.3.1.2 Market Forecast
        10.3.2 France
           10.3.2.1 Market Trends
           10.3.2.2 Market Forecast
        10.3.3 United Kingdom
           10.3.3.1 Market Trends
           10.3.3.2 Market Forecast
        10.3.4 Italy
           10.3.4.1 Market Trends
           10.3.4.2 Market Forecast
        10.3.5 Spain
           10.3.5.1 Market Trends
           10.3.5.2 Market Forecast
        10.3.6 Russia
           10.3.6.1 Market Trends
           10.3.6.2 Market Forecast
        10.3.7 Others
           10.3.7.1 Market Trends
           10.3.7.2 Market Forecast
    10.4    Latin America
        10.4.1 Brazil
           10.4.1.1 Market Trends
           10.4.1.2 Market Forecast
        10.4.2 Mexico
           10.4.2.1 Market Trends
           10.4.2.2 Market Forecast
        10.4.3 Others
           10.4.3.1 Market Trends
           10.4.3.2 Market Forecast
    10.5    Middle East and Africa
        10.5.1 Market Trends
        10.5.2 Market Breakup by Country
        10.5.3 Market Forecast
11    SWOT Analysis
    11.1    Overview
    11.2    Strengths
    11.3    Weaknesses
    11.4    Opportunities
    11.5    Threats
12    Value Chain Analysis
13    Porters Five Forces Analysis

    13.1    Overview
    13.2    Bargaining Power of Buyers
    13.3    Bargaining Power of Suppliers
    13.4    Degree of Competition
    13.5    Threat of New Entrants
    13.6    Threat of Substitutes
14    Price Analysis
15    Competitive Landscape

    15.1    Market Structure
    15.2    Key Players
    15.3    Profiles of Key Players
        15.3.1    Abbvie Inc.
           15.3.1.1 Company Overview
           15.3.1.2 Product Portfolio 
           15.3.1.3 Financials 
           15.3.1.4 SWOT Analysis
        15.3.2    Bayer Aktiengesellschaft
           15.3.2.1 Company Overview
           15.3.2.2 Product Portfolio
           15.3.2.3 Financials 
           15.3.2.4 SWOT Analysis
        15.3.3    Biogen Inc.
           15.3.3.1 Company Overview
           15.3.3.2 Product Portfolio 
           15.3.3.3 Financials 
           15.3.3.4 SWOT Analysis
        15.3.4    Bristol-Myers Squibb Company
           15.3.4.1 Company Overview
           15.3.4.2 Product Portfolio 
           15.3.4.3 Financials 
           15.3.4.4 SWOT Analysis
        15.3.5    F. Hoffmann-La Roche AG (Roche Holding AG)
           15.3.5.1 Company Overview
           15.3.5.2 Product Portfolio 
           15.3.5.3 SWOT Analysis
        15.3.6    GlaxoSmithKline Plc
           15.3.6.1 Company Overview
           15.3.6.2 Product Portfolio 
           15.3.6.3 Financials 
           15.3.6.4 SWOT Analysis
        15.3.7    Merck & Co. Inc.
           15.3.7.1 Company Overview
           15.3.7.2 Product Portfolio
           15.3.7.3 Financials 
           15.3.7.4 SWOT Analysis
        15.3.8    Novartis AG
           15.3.8.1 Company Overview
           15.3.8.2 Product Portfolio 
           15.3.8.3 Financials 
           15.3.8.4 SWOT Analysis
        15.3.9    Sanofi S.A.
           15.3.9.1 Company Overview
           15.3.9.2 Product Portfolio
           15.3.9.3 Financials 
           15.3.9.4 SWOT Analysis
        15.3.10    Teva Pharmaceutical Industries Ltd.
           15.3.10.1 Company Overview
           15.3.10.2 Product Portfolio 
           15.3.10.3 Financials 
           15.3.10.4 SWOT Analysis

List of Figures

Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2020
Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2020
Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2020
Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2020
Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2020
Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2015 & 2020
Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million US$), 2021-2026
Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel in Million US$), 2021-2026
Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 7: Global: Multiple Sclerosis Therapies Market Structure
Table 8: Global: Multiple Sclerosis Therapies Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links